Idebenone Accepted by FDA for Priority Review for Leber Hereditary Optic Neuropathy (LHON)
FDA grants Priority Review to idebenone for Leber Hereditary Optic Neuropathy (LHON), a disease for which there are no existing...
Pharmaceutical
Connect Names Gretel von Son as Chief Operating Officer to Drive Growth in Entrepreneurship and Innovation
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Connect, a premier nonprofit organization in San Diego’s innovation ecosystem, dedicated to...
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
~Patient Recruitment Closed~LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ...
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®...
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with...
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and...
Red drop LAB. – a Swiss Startup Transforms Menstrual Blood Into an Innovative Diagnostic Tool
By Transforming Menstruation Into a Medical Resource, Red drop LAB. Gives Women Back Control Over Their Health and Breaks a...
BioNxt Solutions Announces Closing of Shares for Debt Settlement
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased...
Terry Lynch Continues as Capital Markets Advisor and BioNxt Retains Investor Relations Professionals
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased...
Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / Onco-Innovations Limited (CBOE CA:ONCO )(OTCQB:ONNVF )(Frankfurt:W1H) (WKN: A3EKSZ ) ("...
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured...
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema
First European launch of EKTERLY expected in Germany Q4 2025 EKTERLY now approved in the US, EU, UK and Switzerland...
Acclinate Named to Inc. 5000 List of America’s Fastest-Growing Private Companies
BIRMINGHAM, Ala., Sept. 19, 2025 /PRNewswire/ -- Acclinate, the health equity company pioneering community-powered engagement and inclusive clinical trial enrollment,...
Medical Care Technologies Inc. Launches AI Platform for Early Basal Cell Carcinoma Detection
MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered...
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
Acquisition of leading cannabis company marks major milestone in InterCure’s commercial expansion strategy, bringing access to premium American brands and...
Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities
Vancouver, Canada, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
CHMP recommends EU approval of Roche’s subcutaneous formulation of Lunsumio for people with relapsed or refractory follicular lymphoma
Lunsumio provides high and long-lasting response rates, with approximately two-thirds of patients with a complete response in remission after four...
Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker
Ra’anana, Israel, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a biotechnology company focusing...
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
neffy 1 mg and 2 mg doses approved by Japanese regulators neffy offers a new delivery method for epinephrine in...